CT. Results from the Stage 1 and 2 portions of CHAMPION were shown for 104 patients with relapsed or refractory multiple myeloma who acquired received one to three prior treatment regimens at the established maximum tolerated dose of 20/70 mg/m2. In the Phase 2 portion of the study, the entire response rate was 77 %. The clinical benefit rate was 84 %; the median period to response for patients who accomplished a partial response or better was 1.six months ; Kaplan-Meier median duration of response was 15 a few months ; and the Kaplan-Meier median progression-free of charge survival was 10.6 months .These results suggest that the medical efficacy of a therapeutic HPV-16 vaccine could be determined by its capability to induce a strong and broad multifunctional immune response to the HPV-16 oncoproteins E6 and E7. Dialogue This study demonstrates vaccination with synthetic long peptides that represent the complete length of the two oncoproteins E6 and E7 of HPV-16 works well over an interval of 12 to two years for the treating high-grade vulvar intraepithelial neoplasia lesions.